Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Users Online: 486 | Home Print this page Email this page Small font size Default font size Increase font size
POSTER PRESENTATION
Year : 2012  |  Volume : 32  |  Issue : 5  |  Page : 119

PA01.69. Immunological and virological effect of amrita tablate in human immunodeficiency virus positive patients


Indian Drug Research Institute, Motihari, East Champaran, Bihar, India

Correspondence Address:
Brajeshwar Mishra
Indian Drug Research Institute, Motihari, East Champaran, Bihar
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

Purpose: To assess the safety and efficacy of Amrita tablets in human immunodeficiency virus positive patients. Method: The randomized double blind placebo controlled trial carried out 40 HIV positive patients at Ayurvedic Drug Research Institute Motihari Bihar, with permission from Institutional Ethic Committee for achieve the purpose. Out of 40 HIV patients 30 were male and 10 patients of female. The HIV positive patients were randomly assigned to three groups A, B and C. Group A received Amrita tablet. Group B received Amritasava and group C received Placebo. The doses of Amrita tablet, two tabs. And Amritasava 10ml with one cup water twice daily for six months. The hematological investigation was repeated at the end of the study. Result: In study participants, HIV was more common in the 15 30 year's age group. Half of the enrolled patients where from the age group 42% from 30 40 years and 8% from 40 50 age group. It was observed the end of trial period of amrita tablet was marked increase in the number of CD4count and viral load reduced<300 copies/ml. It was also found gradual reduction of clinical feature of early symptomatic stage of HIV disease. Among the participants received Amritasava there was moderate increase in the number of CD4 count, but there was no difference in viral load. Participants was received placebo there was no differences in CD4 count before the six months Conclusion: Amrita tab. is an ideal herbal formulation .It contain mainly standardchemically defined Asava of Amrita (Tinospora cardifolia) ashwagandha (Withania somnifera) and yasthimadhu (Glycyrrhiza glabra). It increases in number of CD4 count and reduce viral load. It is safe and no adverse toxic effect on long therapy. Now it is necessary to evaluate the physiological activity, pharmacological property toxicity and determination of structure of amrita tab. To antiretroviral classes of drug for used in the health care systems of countries with in the Region and elsewhere in the world.


[PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1545    
    Printed37    
    Emailed0    
    PDF Downloaded38    
    Comments [Add]    

Recommend this journal